CARGO Therapeutics

CARGO Therapeutics is mission-driven to develop 'smarter' CAR T-cell therapies that deliver durable remissions for cancer patients who relapse after current cell therapies. Its core achievement is advancing CRG-022, a CD22-directed CAR T-cell therapy, into a pivotal Phase 2 trial for CD19 CAR T-refractory large B-cell lymphoma, a population with a dire prognosis. The company's strategy leverages a proprietary platform integrating switch technology and cytokine armoring to enhance T-cell fitness and overcome the immunosuppressive tumor microenvironment. CARGO aims to establish a new standard in cell therapy by systematically addressing the biological limitations of first-generation products.

A proprietary cell engineering platform integrating switch technology to regulate CAR activity and improve T-cell fitness, cytokine armoring (e.g., IL-18) to remodel the tumor microenvironment, and strategies for multi-antigen targeting to prevent antigen escape.

Competes with approved bispecific antibodies (e.g., glofitamab) in the post-CAR T space and other biotechs developing CD22-targeted therapies. Differentiation hinges on the potential for more durable responses from its engineered CAR T platform compared to off-the-shelf antibodies.